FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia

The FDA has approved a phase III clinical trial to assess the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.

Source: CancerNetwork - March 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news